The majority of analyst ratings for Hoth Therapeutics are positive, indicating a bullish sentiment towards the stock. However, the decrease in the average 12-month price target suggests that analysts have lowered their expectations for the stock's performance. This could lead to short-term upward pressure on the stock price, but the lowered price target may also indicate potential headwinds in the future.